Mirum Pharmaceuticals

To read more about what this means for the PSC community, read the announcement: bit.ly/3R1xm4G

Learn more about today’s announcement: bit.ly/3R1xm4G

Results from the VISTAS study of volixibat underscore our commitment to advancing potential new options to address one of the most burdensome symptoms for people living with primary sclerosing cholangitis. Learn more: bit.ly/3R1xm4G #PSC #PrimarySclerosingCholangitis

Today, we announced that the VISTAS study, evaluating volixibat in patients with primary sclerosing cholangitis (PSC), met its primary endpoint, showing statistically significant and clinically meaningful reductions in pruritus. These results represent an important step toward addressing one of the most burdensome symptoms experienced by people living with PSC. Full VISTAS results will be presented in a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) International Liver Congress on May 30 at 2:15 pm CEST. Read more: bit.ly/3R1xm4G #PSC #PrimarySclerosingCholangitis

At Mirum, we believe meaningful impact often begins with small actions taken together. Last week, #TeamMirum celebrated Earth Day with a plant swap, encouraging each other to get outside, tend to gardens, and find ways to be more environmentally conscious. It was a great opportunity to reflect on how we can all contribute to protecting our planet, today and every day. #EarthDay

Join us on Wednesday, May 6th, at 1:30pm PT/4:30pm ET, as we share first quarter 2026 results and provide a corporate update. Register for the webcast here: bit.ly/4df3MRV #MIRM #FinancialResults

#TeamMirum is heading to DDW 2026! We look forward to connecting with the gastroenterology and hepatology community, sharing insights, and continuing conversations that support innovation in rare disease care. Visit us at Booth 5041! #DDW2026

Read the announcement here: bit.ly/4ecDDEo    #ChronicHepatitisDeltaVirus #HDV

To learn more about today’s announcement, read the release here: bit.ly/4ecDDEo   #ChronicHepatitisDeltaVirus #HDV

Phase 2b results from the AZURE-1 study of brelovitug underscore our commitment to addressing the urgent needs of people living with HDV. Learn more: bit.ly/4ecDDEo   #ChronicHepatitisDeltaVirus #HDV

Today, we announced that we met the primary endpoint of the Phase 2b AZURE-1 study, evaluating brelovitug in people living with chronic hepatitis delta virus (HDV). These results represent another important step towards advancing potential new treatment options for this serious liver disease. Read more: bit.ly/4ecDDEo #ChronicHepatitisDeltaVirus #HDV

Rare disease demands urgency and sustained commitment. Relentlessly Rare is more than a campaign—it’s how we show up every day: advancing innovative science, partnering with patient communities, and pushing forward where unmet need remains. We’ve redesigned our website to better reflect who we are and how we work. Discover what’s new at mirumpharma.com

We were grateful to be part of this year’s 2026 PSC Partners Conference—an inspiring event that brought the community together in a meaningful way. It was a privilege to listen, learn, and connect with patients, caregivers, and advocates, and to be part of conversations that continue to move the PSC community forward. Thank you to PSC Partners for hosting such a wonderful event—we’re proud to stand alongside this community. #PSC #PSCPartners #RareDisease #Mirumers

We’re proud to share that Mirum has been Great Place to Work™ certified! This recognition is especially meaningful because it’s based on feedback from our employees, the people who make Mirum what it is every day. Learn more about what makes Mirum a great place to work: greatplacetowork.com/certified-comp… #GreatPlacetoWork2026 #TeamMirum

Every day, our Medical Science Liaisons collaborate with the rare disease community—advancing understanding, fostering collaboration, and helping bring patient needs to the forefront. On Medical Science Liaison Day, we recognize and thank these dedicated teams for their expertise, partnership, and unwavering commitment to patients. #MedicalScienceLiaisonDay #RareDisease

Mirum recently hosted its annual ICON meeting in Lisbon, bringing together 57 hepatology experts from around the world for two days of case-based scientific exchange in cholestatic liver disease. The program featured complex real-world PFIC and ALGS discussions, expert-led sessions on pruritus management and genetics, and collaboration across pediatric and adult care. Meetings like ICON play an important role in advancing rare liver disease care, bringing together shared expertise and real-world learning. #TeamMirum #Hepatology #ScientificExchange

Stories like Chord’s remind us why raising awareness for rare disease matters every day.   Thank you to Chatham Daily News for spotlighting Chord and sharing a glimpse into life with Alagille syndrome (ALGS). Greater visibility helps create stronger connections and support for the ALGS community.  Read more here: bit.ly/4s9UBY2 (external link) #RareDiseaseAwareness #ALGS

For more information about today’s announcement, visit bit.ly/4snNSd9.

Momentum continues with enrollment now complete in our Phase 3 EXPAND study evaluating LIVMARLI® (maralixibat) in additional rare cholestatic liver diseases. This exciting milestone brings us one step closer to potentially broadening access to therapy for those who continue to face limited treatment options.    Check out today's announcement: bit.ly/4snNSd9

#TeamMirum is here at ACMG 2026! We’re excited to engage with the medical genetics community, exchange insights, and continue advancing conversations that support rare disease care. Come say hello at booth 2306. We hope to see you there! #ACMG2026 #medicalgenetics #rarediseasecare